BIO 2026: Strategic Cross-Border Asset Sourcing with Protheragen

Online Inquiry

---

As the global biopharmaceutical industry converges on San Diego for the 2026 BIO International Convention (June 22–25 at The San Diego Convention Center), cross-border collaboration remains the primary engine driving therapeutic innovation.

For pharmaceutical companies seeking to enrich their pipelines, and investment groups scouting for high-quality assets, identifying the right partner can be a complex challenge. Protheragen is positioned to bridge that gap.

Headquartered in New York, Protheragen is a premier US-based group specializing in global biopharmaceutical strategic consulting, asset incubation, development, and out-licensing. Actively serving as a Global Strategic Bridge, we operate on a dual-hub model with on-the-ground, cross-functional teams in both the US and China. Backed by over a decade of transaction expertise, Protheragen maintains an extensive ecosystem encompassing 300+ robust partner relationships and a proprietary vault of 700+ validated assets.

Unlocking Diverse Pharmaceutical Assets

Protheragen stands out as a highly specialized and resource-rich strategic partner. Unlike traditional advisory firms, we possess deep-rooted technical insights and a comprehensive understanding of asset positioning. Our current portfolio features a massive selection of innovative, high-potential projects meticulously curated to meet the diverse strategic needs of global buyers.

Our available assets spans from early-stage discovery to late-stage clinical development, offering tailored entry points for partners with varying risk profiles and strategic timelines. Our diverse portfolio includes, but is not limited to:

• Innovative Small Molecules: Next-generation targeted therapies with optimized drug-like properties.
• Advanced Antibodies: High-affinity monoclonal antibodies (mAbs), bispecific/trispecific antibodies, and novel multi-specific platforms.
• Antibody-Drug Conjugates (ADCs): Cutting-edge conjugate technologies designed for precise targeting and enhanced therapeutic indexes.
• Cell and Gene Therapies (CGT): Transformative modalities addressing critical unmet medical needs.

Why Partner with Protheragen?

Protheragen operates as a comprehensive operational, developmental, and strategic incubation platform. We identify promising early-stage innovations, accelerate their development through scientific and regulatory expertise, and structure compliant, high-value out-licensing or co-development transactions.

When you collaborate with Protheragen, you gain immediate access to:

• Scientific and Commercial Synergy: Our multidisciplinary team integrates PhD-level scientific insights with rigorous, execution-focused global business development.
• Cross-Border De-risking: With native operational teams in key global hubs, we seamlessly navigate cultural, regulatory, and legal complexities, ensuring secure, compliant, and efficient transactional risk management.
• Precision Matching: Tell us your target therapeutic area, modality preference, or clinical stage, and our team will rapidly match you with premium, validated assets from our resource vault.

Meet Us in San Diego – Schedule a Session via BIO Partnering™

Protheragen will be on-site throughout BIO 2026. We invite pharmaceutical executives, business development leads, and strategic investment professionals to meet with our senior leadership team in person.

Whether you are looking to acquire a promising asset to bolster your portfolio, or seeking a highly efficient partner to help navigate cross-border asset sourcing, Protheragen is your definitive gateway to global innovation.

• Event: 2026 BIO International Convention
• Date: June 22–25, 2026
• Location: The San Diego Convention Center, San Diego, CA
• How to Connect: Our partnering calendar is now officially open. Search for Protheragen via the official BIO Partnering™ system to schedule a private one-on-one meeting with our BD team.

Let’s advance the future of medicine together. We look forward to meeting you in San Diego! For advanced inquiries or to coordinate schedules prior to the event, please contact our global business development team directly via our official channels.

About Protheragen

Our core services aim to precisely connect innovative pharmaceutical assets with potential partners worldwide.

Core Identity: A Global Strategic Bridge

• Dual-Hub Presence: Headquartered in New York with on-the-ground teams in both the US and China.
• Multidisciplinary Team: Integrates PhD-level scientific insight, global business development (BD) execution, and cross-border legal/transactional risk management.
• Proven Track Record: Over 10 years of expertise in cross-border transactions, managing 300+ partner relationships and a vault of 700+ real assets.